# Questions About Four Endogenous Origins > FAQ: Research Peptide Fundamentals — Primitive Peptides — Cited answers on Research Peptide Fundamentals research peptides — NAD+, KPV, PT-141 (bremelanotide) and GHK-Cu — including what each one is, what the studies measured, and whether endogenous origin implies safety. **FREQUENTLY ASKED** Answers drawn from the same twenty-two sources listed on the references page, with every quantitative claim tied to one of them. ## What is NAD supplement used for? In the published human trials, NAD+ precursor supplements are studied as a way to raise NAD+, a coenzyme every cell already makes and whose tissue level falls with age. The measured endpoints have been mostly biochemical: nicotinamide riboside at 100 to 1000 mg per day for eight weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively in healthy overweight adults [5], and oral NMN at 300 to 900 mg per day for 60 days raised blood NAD+ across all dose groups while improving walking distance and quality-of-life scores [2]. Beyond that, a 2025 review of the human evidence in ageing concluded efficacy remains limited and tissue-level data sparse [1]. Marketed uses run considerably wider than that record. ## What is the downside of taking NAD+? Several are documented. Oral NAD+ itself is poorly taken up by cells intact, which is why precursors rather than NAD+ capsules are generally considered the rational oral route. Intravenous NAD+ therapy is marketed far beyond its controlled evidence, is cleared rapidly from plasma, and can cause chest or abdominal discomfort, flushing and nausea when infused too quickly. Compounded injectable NAD+ has been the subject of an FDA Class I recall for elevated bacterial endotoxin. A theoretical oncology concern is documented, since NAD+ supports proliferating cells and has dual, context-dependent roles in cancer biology. Supplement purity varies and third-party testing is not guaranteed. Finally, the regulatory status of NMN is contested by the FDA. ## Is it safe to take NAD daily? The controlled trials report daily oral dosing without safety problems at the doses and durations tested: nicotinamide riboside at 100 to 1000 mg per day for eight weeks produced no flushing and no significant difference in adverse events versus placebo [5], and NMN at 300 to 900 mg per day for 60 days reported no safety issues at any dose [2]. Those are specific, time-limited studies, not a general safety clearance — long-term daily use beyond those windows has not been characterised, and injectable and intravenous forms carry a separate set of risks including a documented endotoxin recall. This site states no dose for any individual and offers no medical advice. ## Does NAD cause weight gain? Nothing in the cited human evidence points that way. In a ten-week trial of oral NMN at 250 mg per day in prediabetic postmenopausal women, muscle insulin sensitivity improved with no change in body composition and no change in HbA1c [3]. A separate 60-day multicentre NMN trial reported improved walking distance and no safety issues at any dose [2]. Weight gain is not a reported finding in the trials assembled in this corpus, and neither is weight loss — body composition simply did not move in the study designed to measure it [3]. ## What is KPV peptide? KPV is the linear tripeptide lysine-proline-valine, molecular formula C16H30N4O4. It corresponds to residues 11 to 13, the C-terminal end, of alpha-melanocyte-stimulating hormone, and the literature also writes it as alpha-MSH(11-13). Nothing about it is modified: it is the same three amino acids in the same order as the last three of the human hormone. It is not an approved drug or dietary supplement in any major jurisdiction and is sold by chemical suppliers for laboratory research use only. No published human clinical trial of KPV exists. ## What does KPV peptide do? In cell and animal models it suppresses NF-kB and MAP-kinase signalling and reduces production of pro-inflammatory cytokines including IL-1beta and TNF-alpha [8]. In the gut it is carried directly into epithelial cells by PepT1, a transporter that accepts only di- and tripeptides and that is upregulated in inflamed intestinal tissue [8]. Notably, it does not appear to work the way its parent hormone does: activity was retained in mice lacking MC1R [9], and a receptor-level analysis concluded KPV is unlikely to act through melanocortin receptors at all, proposing inhibition of IL-1beta function instead [12]. All of this is preclinical. ## What is PT-141? PT-141 is bremelanotide, a synthetic cyclic heptapeptide lactam analogue of alpha-melanocyte-stimulating hormone, with a lactam bridge between the aspartate and lysine side chains and two unnatural amino-acid substitutions. It is a structural relative of melanotan II. It activates central melanocortin receptors, chiefly MC4R, in hypothalamic and limbic circuits governing sexual desire, which distinguishes it from PDE-5 inhibitors that act peripherally on vascular smooth muscle. It was approved by the FDA in June 2019 for one indication and is marketed as Vyleesi; material sold as "PT-141 research chemical" sits outside that approval. ## What is PT-141 used for? The approved use is narrow: acquired, generalised hypoactive sexual desire disorder in premenopausal women [17]. Two identical Phase 3 trials in 1,267 women met their co-primary endpoints, improving sexual desire by an integrated FSFI-desire score of +0.35 and reducing desire-related distress by −0.33 versus placebo over 24 weeks, both at P<.001 [15]. Use in men, in postmenopausal women or for sexual performance is off-label and outside the studied population. This digest reports the indication and trial outcome, not a regimen for any person. ## What does a GHK-Cu peptide do? GHK-Cu acts as both a copper chaperone and a broad signalling molecule. At picomolar to nanomolar concentrations it stimulates dermal fibroblasts to synthesise collagen, elastin, glycosaminoglycans and decorin, and rebalances matrix metalloproteinases against their TIMP inhibitors; the bound copper enables lysyl-oxidase cross-linking and superoxide-dismutase-like antioxidant activity. Gene-expression analysis reports it alters expression of about 31.2% of human genes at a 50%-or-greater change threshold, 59% increased and 41% suppressed [19]. In controlled human work, topical GHK-Cu increased collagen production in 70% of treated women, against 50% for vitamin C and 40% for retinoic acid [21]. ## What is the difference between GHK and GHK-Cu? GHK is the bare tripeptide glycine-histidine-lysine. GHK-Cu is that peptide chelated to a copper(II) ion in a 1:1 complex, coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen. The distinction is not cosmetic: most of the documented tissue-remodelling activity depends on the copper being properly coordinated, and the plain peptide without copper does not reproduce key effects such as MMP-2 stimulation in cell studies. The two are frequently conflated in secondary sources, which makes the form used in any given study a material fact about that study. ## Is GHK-Cu peptide really anti-aging? The honest answer is that the human evidence is real, small and topical, and the claims made for it are large and systemic. Plasma GHK does fall from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [21], and controlled topical work shows procollagen increases in 70% of treated subjects versus 50% for vitamin C and 40% for retinoic acid [18][21]. Against that, human data is limited to small dermatology trials and one 45-participant hair study of a combination formulation [20], much of the mechanistic literature originates from a single research group, and the widely quoted "about 4,000 genes" figure is an extrapolation from a verified statistic covering roughly 2,100 genes [19]. ## Does a compound the body already makes carry a safety advantage? Not by virtue of its origin. Endogenous provenance describes where a molecule came from; it sets none of the variables that determine what happens when the molecule is administered — dose, route, concentration, frequency and off-target binding. The clearest demonstration sits in this catalogue. Bremelanotide descends from a human hormone and is reported to darken skin, gums and moles with frequent repeated dosing, because the receptor family it targets also governs pigment [17]. NAD+ is chemically identical to the endogenous coenzyme, its blood level rises reliably [5], and the 2025 review of human trials in ageing still described efficacy as limited [1]. A natural sequence delivered on a schedule physiology never uses is a new pharmacological event. --- Primitive Peptides traces four research compounds back to the molecules the body makes on its own, and treats endogenous origin as a starting hypothesis rather than a safety claim — a literature digest, not a clinic, a vendor, or a source of dosing advice.